NCT00378599View on ClinicalTrials.gov

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Liver TransplantationHepatitis C, ChronicLiver Cirrhosis
Interventions
DRUG

Combination of (a) pegylated interferon alfa-2b and (b) rebetol

"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00378599 - Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) | Biotech Hunter | Biotech Hunter